Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
Illumina (NASDAQ: ILMN) and Tempus AI (NASDAQ: TEM) have announced a strategic collaboration to accelerate the clinical adoption of next-generation sequencing tests through AI-driven innovation. The partnership aims to combine Illumina's AI technologies with Tempus's multimodal data platform to enhance genomic algorithms and expand molecular profiling across various disease categories.
The collaboration focuses on developing evidence to standardize comprehensive genomic profiling and molecular testing beyond cancer, extending to cardiology, neurology, and immunology. This builds upon the companies' existing partnership in developing tools and assays for testing needs from preemptive screening through therapy selection.
The initiative addresses the current gap where patients often miss precision medicine benefits due to non-standardized molecular profiling across disease areas and regions. The partnership will leverage data analytics and sequencing technologies to improve patient outcomes and advance precision medicine research.
Illumina (NASDAQ: ILMN) e Tempus AI (NASDAQ: TEM) hanno annunciato una collaborazione strategica per accelerare l'adozione clinica dei test di sequenziamento di nuova generazione attraverso l'innovazione guidata dall'intelligenza artificiale. La partnership punta a unire le tecnologie AI di Illumina con la piattaforma di dati multimodali di Tempus per migliorare gli algoritmi genomici e ampliare il profilo molecolare in diverse categorie di malattie.
La collaborazione si concentra sullo sviluppo di evidenze per standardizzare il profilo genomico completo e i test molecolari oltre il cancro, estendendosi a cardiologia, neurologia e immunologia. Questo si basa sulla partnership esistente tra le due aziende per sviluppare strumenti e test che coprono le esigenze dalla diagnosi precoce alla selezione della terapia.
L'iniziativa affronta la lacuna attuale per cui i pazienti spesso non beneficiano della medicina di precisione a causa della mancanza di standardizzazione nel profilo molecolare tra aree patologiche e regioni diverse. La collaborazione sfrutterà l'analisi dei dati e le tecnologie di sequenziamento per migliorare i risultati clinici e promuovere la ricerca nella medicina di precisione.
Illumina (NASDAQ: ILMN) y Tempus AI (NASDAQ: TEM) han anunciado una colaboración estratégica para acelerar la adopción clínica de pruebas de secuenciación de próxima generación mediante innovación impulsada por inteligencia artificial. La asociación busca combinar las tecnologías de IA de Illumina con la plataforma de datos multimodales de Tempus para mejorar los algoritmos genómicos y ampliar el perfil molecular en diversas categorías de enfermedades.
La colaboración se centra en desarrollar evidencia para estandarizar el perfil genómico integral y las pruebas moleculares más allá del cáncer, extendiéndose a cardiología, neurología e inmunología. Esto se basa en la asociación existente entre ambas compañías para desarrollar herramientas y ensayos que cubren las necesidades de pruebas desde el cribado preventivo hasta la selección de terapias.
La iniciativa aborda la brecha actual donde los pacientes a menudo no se benefician de la medicina de precisión debido a la falta de estandarización en el perfil molecular entre áreas de enfermedad y regiones. La colaboración aprovechará el análisis de datos y las tecnologías de secuenciación para mejorar los resultados clínicos y avanzar en la investigación de la medicina de precisión.
Illumina (NASDAQ: ILMN)와 Tempus AI (NASDAQ: TEM)가 AI 기반 혁신을 통해 차세대 시퀀싱 검사 임상 도입을 가속화하기 위한 전략적 협력을 발표했습니다. 이번 파트너십은 Illumina의 AI 기술과 Tempus의 다중 모달 데이터 플랫폼을 결합하여 유전체 알고리즘을 향상시키고 다양한 질병 범주에서 분자 프로파일링을 확장하는 것을 목표로 합니다.
협력은 암을 넘어 심장학, 신경학, 면역학 분야까지 포괄적인 유전체 프로파일링과 분자 검사 표준화를 위한 근거 개발에 중점을 둡니다. 이는 사전 선별부터 치료 선택에 이르는 검사 요구를 충족하기 위한 도구 및 분석법 개발에 관한 기존 파트너십을 기반으로 합니다.
이 이니셔티브는 환자들이 질병 분야와 지역별로 분자 프로파일링이 표준화되지 않아 정밀 의학의 혜택을 받지 못하는 현재의 격차를 해소하고자 합니다. 이번 협력은 데이터 분석과 시퀀싱 기술을 활용해 환자 치료 결과를 개선하고 정밀 의학 연구를 진전시킬 것입니다.
Illumina (NASDAQ : ILMN) et Tempus AI (NASDAQ : TEM) ont annoncé une collaboration stratégique visant à accélérer l'adoption clinique des tests de séquençage de nouvelle génération grâce à l'innovation pilotée par l'intelligence artificielle. Ce partenariat vise à combiner les technologies d'IA d'Illumina avec la plateforme de données multimodales de Tempus afin d'améliorer les algorithmes génomiques et d'étendre le profilage moléculaire à diverses catégories de maladies.
La collaboration se concentre sur le développement de preuves permettant de standardiser le profilage génomique complet et les tests moléculaires au-delà du cancer, en s'étendant à la cardiologie, la neurologie et l'immunologie. Elle s'appuie sur le partenariat existant entre les deux entreprises pour développer des outils et des tests répondant aux besoins, du dépistage préventif à la sélection thérapeutique.
Cette initiative répond à la lacune actuelle où les patients ne bénéficient souvent pas de la médecine de précision en raison d'un profilage moléculaire non standardisé selon les maladies et les régions. Le partenariat exploitera l'analyse des données et les technologies de séquençage pour améliorer les résultats des patients et faire progresser la recherche en médecine de précision.
Illumina (NASDAQ: ILMN) und Tempus AI (NASDAQ: TEM) haben eine strategische Zusammenarbeit angekündigt, um die klinische Einführung von Next-Generation-Sequenzierungstests durch KI-gestützte Innovation zu beschleunigen. Die Partnerschaft zielt darauf ab, Illuminas KI-Technologien mit der multimodalen Datenplattform von Tempus zu kombinieren, um genomische Algorithmen zu verbessern und die molekulare Profilierung in verschiedenen Krankheitsbereichen auszuweiten.
Der Fokus der Zusammenarbeit liegt auf der Entwicklung von Evidenzen zur Standardisierung umfassender genomischer Profilierungen und molekularer Tests über Krebs hinaus, mit Erweiterungen auf Kardiologie, Neurologie und Immunologie. Dies baut auf der bestehenden Partnerschaft der Unternehmen auf, Werkzeuge und Tests für den Bedarf von präventivem Screening bis hin zur Therapieauswahl zu entwickeln.
Die Initiative adressiert die derzeitige Lücke, dass Patienten oft nicht von Präzisionsmedizin profitieren, da molekulare Profilierungen in verschiedenen Krankheitsgebieten und Regionen nicht standardisiert sind. Die Partnerschaft wird Datenanalyse und Sequenzierungstechnologien nutzen, um Behandlungsergebnisse zu verbessern und die Forschung in der Präzisionsmedizin voranzutreiben.
- Strategic expansion into multiple disease categories beyond cancer
- Enhancement of AI-driven molecular analysis technologies
- Access to Tempus's comprehensive multimodal data platform
- Dependency on third-party suppliers for critical components
- Uncertainties in manufacturing robust instrumentation and consumables
- Risk of new products not meeting customer expectations
Insights
Illumina's strategic partnership with Tempus AI represents a calculated move to expand the clinical adoption of next-generation sequencing beyond its traditional stronghold in oncology. By combining Illumina's sequencing expertise with Tempus's multimodal data platform, the collaboration aims to develop compelling evidence packages that could potentially standardize molecular profiling across multiple disease categories including cardiology, neurology, and immunology.
This partnership addresses a fundamental challenge in precision medicine: the need for robust clinical evidence demonstrating the value of genomic profiling. For Illumina, whose core business centers on sequencing technologies, expanding clinical applications represents a critical market growth opportunity. The sequencing giant has faced increasing competition in its core technology space, making partnerships that create new demand drivers strategically important.
What's particularly valuable about this collaboration is Tempus's real-world data assets, which Illumina can leverage to generate the evidence packages needed for broader clinical adoption and potential reimbursement approvals. This evidence-generation approach could accelerate the inclusion of comprehensive genomic profiling in clinical guidelines across multiple therapeutic areas.
While the announcement lacks specific financial terms or revenue projections, the focus on AI-driven molecular analysis technologies suggests Illumina is strategically positioning itself to maintain relevance in an increasingly data-driven precision medicine landscape. For investors, this represents a longer-term growth initiative rather than an immediate revenue catalyst, but one that addresses crucial expansion needs in Illumina's evolving business model.
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease
"In the era of true precision medicine, every patient who is battling complex disease should be routed to the optimal therapy based on molecular insights," said Everett Cunningham, chief commercial officer of Illumina. "We envision a world where the full range of molecular profiling is available as part of the standard of care—not just in cancer, but in cardiology, neurology, immunology, and every other category of disease."
Today, patients frequently miss the benefit of precision medicine because molecular profiling is not yet standard across disease areas and regions. This collaboration will leverage Tempus multimodal data to further improve Illumina's AI-driven molecular analysis technologies and generate new insights supporting the clinical value of sequencing. These insights will be used to build evidence packages needed to standardize use of comprehensive genomic profiling and other molecular testing across all major diseases.
"By expanding our collaboration with Illumina, we are combining our strengths in technology and data analytics with their strengths in developing new sequencing technologies to drive forward innovation and advance precision medicine," said Terron Bruner, chief commercial officer of Tempus.
The program builds on a long-standing collaboration between the companies, which has focused on developing tools and assays to address gaps in testing needs from preemptive screening through therapy selection, health economics, and bioinformatics pipelines to improve patient outcomes and research.
Use of forward-looking statements (Illumina)
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements (Tempus)
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of biological modeling solutions in therapeutic research and discovery, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Contacts
Investors:
Brian Blanchett
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
Erin Carron
media@tempus.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-and-tempus-partner-to-drive-the-future-of-precision-medicine-through-genomic-ai-innovation-302428526.html
SOURCE Illumina, Inc.
FAQ
What is the main objective of the Illumina-Tempus collaboration announced in 2025?
How will the ILMN partnership with Tempus benefit patient care?
What disease areas will the ILMN-Tempus collaboration focus on beyond cancer?
What existing partnership areas does this new ILMN-Tempus collaboration build upon?
